

# CHRD 2024: Abstract Submission Form

**Presenter Name**

Sherif Eltonsy (4)

**Presenter Status**

Non-Trainee

**Role in the project**

Design  
Perform Experiments  
Analyze Data  
Write Abstract

**Research Category**

Community Health / Policy

**Title**

Gabapentin Use During Pregnancy and the Risk of Adverse Neonatal Birth Outcomes in two Canadian provinces

**Background**

Over the last decade, gabapentin has become one of the most utilized antiseizure medications during pregnancy, with its increased off-label use attributed to perceived safety and efficacy in pain reduction.

**Objective**

We aimed to study the association between in-utero exposure to gabapentin and adverse neonatal outcomes among all pregnant people, pregnant people with epilepsy (PPWE) and pregnant people without epilepsy (PPWOE.), in two Canadian provinces.

**Methods**

We conducted a multi-site population-based retrospective cohort study of pregnant people in Manitoba (1998-2021) and Saskatchewan (1995-2023). We examined the association between gabapentin exposure anytime during pregnancy and the following outcomes: risk of small for gestational age (SGA), low birth weight (LBW), preterm birth, NICU admissions, infants' length of hospital stays (LOS) (> 3 days), infant mortality ( $\leq 27$  days), neonatal mortality ( $\leq 365$  days), severe neonatal morbidity (SNM) and neonatal readmissions. This analysis was done among all pregnant people, PPWE and PPWOE. Multivariate regression models were adjusted for maternal age, pain, comorbidities, urban/rural, socioeconomic status, multiple births, and teratogenic drugs exposure in first trimester. Random effects model was used to meta-analyze the aggregated data from both sites.

**Results**

We included a total of 545,121 pregnancies in our analysis including 1,663 (0.31%) pregnancies exposed to gabapentin. We observed a significant increase in the risk of SGA (adjusted odds ratio [aOR] 1.19, 95%CI 1.06-1.33), preterm birth (aOR 1.62, 95%CI 1.37-1.91), LOS infant (aOR 1.82, 95%CI 1.40-2.36), infant mortality (aOR 1.48, 95%CI 1.04-2.11), neonatal mortality (aOR 1.56, 95%CI 1.04-2.34), neonatal readmissions (aOR 1.29, 95%CI 1.02-1.64), SNM (aOR 1.22, 95%CI 1.08-1.38). No significant association was observed with LBW (aOR 1.19, 95%CI 0.45-3.12), and NICU admissions (aOR 1.57, 95%CI 0.97-2.60), when compared with unexposed pregnant people. Similar significant increased risks were observed among PPWOE. The PPWE analysis was underpowered therefore the models didn't converge. The findings were consistent between the two sites.

**Conclusion**

Gabapentin exposure in all pregnant people and PPWOE were associated with a significant increase in specific adverse birth outcomes among infants. Clinicians should be aware of the benefits and potential risks of prescribing gabapentin during pregnancy. In particular for non-epilepsy indications where use during pregnancy may be avoided. Future studies investigating gabapentin dose and safety are warranted.

Alekhya Lavu<sup>1</sup>, Payam Peymani<sup>1</sup>, 1, Chelsea Ruth<sup>2,1</sup>, Kaarina Kowalec<sup>1</sup>, Christine Leong<sup>1</sup>, Shelley Derksen<sup>3</sup>, Roxana Dragan<sup>3</sup>, Marcus C Ng<sup>4</sup>, Brandace Winquist<sup>5</sup>, Joseph Delaney<sup>1</sup>, Sherif Eltonsy<sup>1</sup>

**Do you have a table/figure to upload?**

No

## Authors

Name	Email	Role	Profession
Alekhya Lavu		Co Author	Graduate
Payam Peymani			
Silvia Alessi Severini			
Chelsea Ruth			
Jamison Falk			
Kaarina Kowalec			
Christine Leong			
Shelley Derksen			
Roxana Dragan			
Marcus C Ng			
Brandace Winqvist			
Joseph Delaney			
Sherif Eltonsy		Presenting Author	Assistant Professor